Open Medscience

AUGUST 11, 2024

Radiopharmaceuticals in diagnostics provide critical insights into disease processes, improving accuracy, patient care, and treatment outcomes significantly. The post The Transformative Power of Radiopharmaceuticals in Diagnostics appeared first on Open MedScience.

Radiopharmaceuticals 52

Radiopharmaceuticals Diagnostic Patient Care Disease 52

Open Medscience

JANUARY 1, 2024

Zirconium radiopharmaceuticals enhance nuclear medicine with precise diagnostics and potential therapeutic applications. The post Zirconium Radiopharmaceuticals in Nuclear Medicine appeared first on Open Medscience.

Nuclear Medicine 59

Nuclear Medicine Radiopharmaceuticals Diagnostic Medical 59

Imaging Technology

MAY 10, 2024

milla1cf Fri, 05/10/2024 - 08:08 May 10, 2024 — Mariana Oncology , a fully integrated biotechnology company pioneering a new era of radiopharmaceutical innovation to treat people with cancer , today announced it will be acquired by Novartis for $1 billion upfront and up to $750 million in potential milestone payments.

Radiopharmaceuticals 95

Radiopharmaceuticals Clinic IT 95

Open Medscience

NOVEMBER 17, 2023

Gallium, predicted by Mendeleev, now revolutionises medical diagnostics with its unique radiopharmaceutical applications in oncology. The post Gallium Radiopharmaceuticals in Medical Imaging appeared first on Open Medscience.

Radiopharmaceuticals 59

Radiopharmaceuticals Medical Imaging Medical Imaging 59

Open Medscience

JUNE 17, 2024

Radiopharmaceuticals play a crucial role in heart imaging, enabling accurate diagnosis and effective treatment of various cardiac conditions. The post Radiopharmaceuticals in Heart Imaging for Diagnosis and Treatment appeared first on Open MedScience.

Radiopharmaceuticals 52

Radiopharmaceuticals Imaging 52

Open Medscience

FEBRUARY 28, 2024

Exploring the evolving role of radiopharmaceutical diagnostics in enhancing disease detection and personalising treatment in modern medicine. The post Radiopharmaceutical Diagnostics and Imaging Technologies appeared first on Open Medscience.

Radiopharmaceuticals 52

Radiopharmaceuticals Diagnostic Imaging Disease 52

Open Medscience

DECEMBER 31, 2023

Lutetium radiopharmaceuticals significantly advance targeted cancer treatment and diagnostic capabilities. The post Lutetium Radiopharmaceuticals in Medicine: A Comprehensive Review appeared first on Open Medscience.

Radiopharmaceuticals 59

Radiopharmaceuticals Diagnostic Medical Imaging 59

Open Medscience

JUNE 23, 2024

What are radiopharmaceuticals? The post What are Radiopharmaceuticals? They are radioactive drugs used for diagnosing and treating various medical conditions. An Insight into Their Role and Applications appeared first on Open MedScience.

Radiopharmaceuticals 52

Radiopharmaceuticals Diagnose Medical 52

Open Medscience

DECEMBER 28, 2023

Lead radiopharmaceuticals herald a transformative era in cancer treatment with promising, targeted therapeutic approaches. The post Transforming Cancer Treatment: The Promising Future of Lead Radiopharmaceuticals appeared first on Open Medscience.

Radiopharmaceuticals 59

Radiopharmaceuticals Medical 59

Open Medscience

JANUARY 12, 2024

Radiopharmaceuticals, combining radioactive and pharmaceutical elements, enable precise diagnosis and treatment in nuclear medicine. The post The Transformative Impact of Radiopharmaceuticals in Medical Imaging appeared first on Open Medscience.

Radiopharmaceuticals 52

Radiopharmaceuticals Medical Imaging Nuclear Medicine Medical 52

Health Imaging

JUNE 15, 2023

According to new research, gliomas—a deadly group of brain tumors that are difficult to treat—have increased folate receptor expression, meaning they also show increased uptake of folate-based radiopharmaceuticals on PET imaging.

Radiopharmaceuticals 96

Radiopharmaceuticals Imaging 96

Open Medscience

NOVEMBER 16, 2023

In Brazil, the growing radiopharmaceutical market, driven by chronic disease and advanced imaging technologies, is becoming increasingly significant in healthcare. The post Advancing Healthcare: The Dynamic Growth of Brazil’s Radiopharmaceutical Market appeared first on Open Medscience.

Radiopharmaceuticals 59

Radiopharmaceuticals Healthcare Healthcare Disease 59

Open Medscience

NOVEMBER 11, 2023

Copper radiopharmaceuticals offer groundbreaking diagnostic and therapeutic applications, revolutionising nuclear medicine, particularly in oncology and cardiology. The post Exploring Copper Radiopharmaceuticals: Innovations and Applications in Nuclear Medicine appeared first on Open Medscience.

Nuclear Medicine 59

Nuclear Medicine Radiopharmaceuticals Diagnostic Medical 59

Open Medscience

JANUARY 24, 2024

The post The Breakthrough Role of Thorium-227 in Theranostic Radiopharmaceuticals appeared first on Open Medscience. Thorium-227 emerges in nuclear medicine, revolutionizing cancer treatment through precise, effective radiotheranostic and therapeutic applications.

Radiopharmaceuticals 64

Radiopharmaceuticals Nuclear Medicine 64

Open Medscience

NOVEMBER 12, 2023

The post Technetium-99m Radiopharmaceuticals in Advanced Medical Imaging appeared first on Open Medscience. Technetium-99m, discovered in 1937, transformed medical imaging with its versatile and safe diagnostic applications.

Radiopharmaceuticals 59

Radiopharmaceuticals Medical Imaging Medical Imaging 59

Open Medscience

MARCH 22, 2024

The post Nuclear Medicine at the Centre of Radiology and Radiopharmaceuticals appeared first on Open Medscience. Nuclear medicine and the future of precise, personalised care in diagnosing and treating diseases.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Radiology Disease 52

AuntMinnie

JUNE 24, 2024

Jubilant Radiopharma plans to invest $50 million to expand its PET radiopharmaceutical manufacturing capacity. The money will be used to add six manufacturing facilities across the U.S. to the company's network, bringing its total to nine. Jubilant expects the new sites to be up and running in about two years, it said.

Radiopharmaceuticals 52

Radiopharmaceuticals IT 52

Imaging Technology

OCTOBER 17, 2023

a clinical stage radiopharmaceutical company focused on the discovery and development of novel agents for the treatment of a wide range of oncology indications, is pleased to announce that the first subject has been dosed in its Phase 1 study of 68Ga-R8760. milla1cf Tue, 10/17/2023 - 13:07 October 17, 2023 — Radionetics Oncology, Inc.,

Radiopharmaceuticals 116

Radiopharmaceuticals Clinic Disease Diagnose 116

Imaging Technology

JANUARY 5, 2024

This leading radiopharmaceutical platform provides detailed PET imaging-based diagnosis and dosimetry using long-lived copper-64 ( 64 Cu) for imaging and alpha-particle targeted RPT using lead-212 ( 212 Pb). milla1cf Fri, 01/05/2024 - 11:21 January 5, 2024 — Perspective Therapeutics, Inc.

Radiopharmaceuticals 104

Radiopharmaceuticals Clinic Nuclear Medicine Radiation 104

Imaging Technology

SEPTEMBER 20, 2023

a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for cancer detection and treatment, announced an exclusive licensing agreement for RefleXion to develop and commercialize a specific 3BP molecule to direct its SCINTIX biology-guided radiotherapy.

Pharmaceutical 105

Pharmaceutical Radiopharmaceuticals Radiation Diagnostic 105

AuntMinnie

JUNE 22, 2023

Read more on AuntMinnie.com Related Reading: RLS appoints new director of regulatory affairs SpectronRx, RLS ink radiopharmaceutical supply deal RLS lands radiopharmaceutical supplier deal from Premier Sofie to launch FAPI-PET phase II trial First patient imaged in Sofie's FAPI-PET trial

Radiopharmaceuticals 52

Radiopharmaceuticals Imaging 52

Imaging Technology

APRIL 10, 2024

an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted therapeutic radiopharmaceutical, is the lead candidate in Blue Earth Therapeutics’ oncology development program of next generation therapeutic radiopharmaceuticals. 177Lu-rhPSMA-10.1,

Radiopharmaceuticals 105

Radiopharmaceuticals Radiosensitivity Medical Diagnostic 105

AuntMinnie

SEPTEMBER 13, 2023

Senate MITA hails radiopharmaceutical legislation Read more on AuntMinnie.com Related Reading: ACR urges full coverage for amyloid PET scans CMS proposal covers PET scans for Alzheimer’s disease MITA praises FDA for Leqembi approval FIND Act reintroduced in U.S.

Radiopharmaceuticals 52

Radiopharmaceuticals PET Scan Medical Imaging Disease 52

AuntMinnie

MAY 8, 2024

Theranostics treatments are used with increasing frequency now since the approvals and expansions of Lutathera (lutetium-177 [Lu-177]) DOTATATE, a radiopharmaceutical for neuroendrocrine tumors (NETs) and Pluvicto, Lu-177 PSMA-617, for prostate cancer.

Radiopharmaceuticals 75

Radiopharmaceuticals Nuclear Medicine Radiation Hospital 75

Health Imaging

JULY 29, 2024

According to the DOJ, the pharmacist and those working under him “would ‘fractionate’ or ‘split’ the active ingredient of Technescan MAG3, without ensuring the pieces were equal in size, purity or strength.”

Radiopharmaceuticals 108

Radiopharmaceuticals 108

Imaging Technology

JULY 25, 2023

By leveraging our expertise in radiopharmaceuticals, we aim to contribute to the early detection and accurate monitoring of epithelial-derived cancers. This further strengthens our commitment to production and development of novel radiopharmaceuticals to advance cancer treatments and quality of life for cancer patients."

Radiopharmaceuticals 98

Radiopharmaceuticals Imaging Pharmaceutical Disease 98

Imaging Technology

JULY 11, 2023

By leveraging our expertise in radiopharmaceuticals, we aim to contribute to the early detection and accurate monitoring of epithelial-derived cancers. This further strengthens our commitment to production and development of novel radiopharmaceuticals to advance cancer treatments and quality of life for cancer patients."

Radiopharmaceuticals 75

Radiopharmaceuticals Imaging Pharmaceutical Disease 75

Imaging Technology

APRIL 5, 2024

milla1cf Fri, 04/05/2024 - 11:31 April 5, 2024 — RLS Radiopharmacies , America’s only Joint Commission-accredited radiopharmacy network, today announced it has expanded its radiopharmaceutical contract development and manufacturing (rCDMO) capabilities by entering into a strategic agreement with global isotope technology leader Eckert & Ziegler.

Radiopharmaceuticals 52

Radiopharmaceuticals Radiation Oncology Radiation Quality and Compliance 52

AuntMinnie

JUNE 8, 2023

Radiopharmaceutical manufacturer SpectronRx and nuclear medicine drug distributo.

Radiopharmaceuticals 52

Radiopharmaceuticals Nuclear Medicine Clinic 52

Imaging Technology

JUNE 15, 2023

The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use.

Radiopharmaceuticals 98

Radiopharmaceuticals Pharmaceutical Nuclear Medicine PET Scan 98

Diagnostic Imaging

JUNE 28, 2023

discussed the potential impact of urinary activity with positron emission tomography (PET) radiopharmaceuticals, and new phase 3 study data that found low urinary activity with the use of the flotufolastat F 18 injectable agent in patients with prostate cancer.

Radiopharmaceuticals 61

Radiopharmaceuticals Nuclear Medicine Imaging 61

Open Medscience

JULY 28, 2019

Radiopharmaceuticals are used in nuclear medicine for the application of medical imaging and therapy. The post Radiopharmaceuticals used in nuclear medicine appeared first on Open Medscience.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Medical Imaging Medical 52

Radiology Business

NOVEMBER 20, 2024

The Australian company will secure exclusive worldwide rights to a suite of diagnostic and therapeutic candidates geared toward urological cancers.

Radiopharmaceuticals 93

Radiopharmaceuticals Imaging Diagnostic 93

Imaging Technology

JANUARY 5, 2024

milla1cf Fri, 01/05/2024 - 11:32 January 5, 2024 — NorthStar Medical Radioisotopes, LLC , a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, and Curadh MTR Inc. Chief Executive Officer of NorthStar Medical Radioisotopes.

Radiopharmaceuticals 52

Radiopharmaceuticals Medical Nuclear Medicine Pharmaceutical 52

Radiology Business

OCTOBER 7, 2024

Founded in 2019, the firm is focused on developing products for the diagnosis and therapy of blood cancers and other indications not addressed by nuclear medicine.

Nuclear Medicine 92

Nuclear Medicine Radiopharmaceuticals 92

Radiology Business

OCTOBER 31, 2024

Leaders said the funding will help Blue Earth to further advance its development of PSMA-targeted therapies for prostate cancer.

Radiopharmaceuticals 91

Radiopharmaceuticals Imaging IT 91

Imaging Technology

NOVEMBER 7, 2024

Under the new policy, CMS will unpackage and pay separately for diagnostic radiopharmaceuticals with per-day costs exceeding $630, removing financial barriers that have long hindered patient access to essential nuclear medicine diagnostic procedures. tim.hodson Thu, 11/07/2024 - 11:25 Nov.

Nuclear Medicine 97

Nuclear Medicine Radiopharmaceuticals Medicare Diagnostic 97